ABSTRACT OBJECTIVES This study aimed to evaluate the specific role of the 2 available mineralocorticoid receptor antagonists (MRAs), eplerenone and spironolactone, on the modulation of galectin-3 (Gal-3) and interleukin (IL)-33/ST2 signaling in an experimental model of left ventricular systolic dysfunction after acute myocardial infarction (MI).
and eplerenone differ in their molecular structure, pharmacodynamics, and pleiotropic effects (7, 8) ;
however, meaningful differences between the 2 agents are not clearly present, and clinical practice guidelines do not discriminate between agents when recommending the use of an MRA in this setting (9, 10) .
Galectin-3 (Gal-3) and soluble ST2 (sST2) are promising prognostic biomarkers that are involved in myocardial remodeling, fibrosis, and inflammation (11) (12) (13) (14) ; both are prognostically meaningful after AMI and in patients with established HF. Gal-3, a soluble b-galactoside-binding lectin, has been associated with activation of fibroblasts and macrophages (12) . In patient cohorts, higher concentrations of plasma Gal-3 are associated with LV remodeling along with an increased risk of incident HF and mortality (15, 16) .
ST2 is an interleukin (IL)-1 receptor family member
with transmembrane (ST2L) and soluble (sST2) isoforms. Through interaction between IL-33 and ST2L, myocardial fibrosis and hypertrophy are prevented (13) ; in contrast, sST2 acts as a decoy receptor that neutralizes IL-33, and the cardioprotective role of IL-33/ST2L signaling pathway is lost (14) , resulting in cardiomyocyte hypertrophy, apoptosis, and fibrosis.
In this context, serum sST2 levels are strongly predictive of adverse outcomes in patients with AMI or HF and significantly predict LV remodeling (17) (18) (19) (20) .
Given the links between Gal-3 and sST2 with myocardial fibrosis and HF progression, it has been frequently speculated that an intersection between MRA therapy and these 2 pathways may exist. However, links between Gal-3 and sST2 with the benefit of the treatment with MRAs have not been clinically elucidated (21) . Accordingly, the present study aimed to evaluate the specific role of the 2 available MRAs, Table 1 ).
STATISTICAL ANALYSIS. Data were expressed as mean AE SEM or SD as stated and were analyzed using SPSS software version 19 (SPSS Inc., Chicago, Illinois). Paired-sample comparisons and 1-way analysis of variance were used as appropriate. Graphing was performed using SigmaPlot 11.0 software (Systat Software Inc., San Jose, California). Statistical significance was assumed at p < 0.05.
RESULTS
Echocardiographic parameters of the respective groups of rats are showed in Table 1 Table 2 ). FIBROSIS. As shown in Figure 3 , in the infarcted area, the expression of collagen type I (Col I) (p < Table 2) . Masson trichrome staining for interstitial fibrosis in the infarcted area is shown in Figure 3D Figure 1) . Figure 4 , the MI group exhibited signs of inflammation in the in- HF (32-34) . In the present study, and nongenomic effects (7, 36, 37) . In addition, observational analyses in contemporary populations receiving spironolactone have not replicated the results obtained by eplerenone in clinical trials (38, 39) . Given the lack of clinical studies, we compared the effects of spironolactone and eplerenone, and the results support that both exert similar favorable myocardial effects after AMI.
INFLAMMATION. As shown in
These benefits are related to the inhibition of the MR and not the modest diuretic effect of these agents (40) ; in fact, we did not find differences in terms of body weight or potassium sparing between groups.
Although data exist suggesting favorable effects of eplerenone on LV remodeling after AMI among those patients with higher sST2 levels (23) Spain. E-mail: dpascual@um.es.
